belimumab

Overview

Belimumab is a biologic therapy used in systemic lupus erythematosus (SLE). It is a monoclonal antibody designed to inhibit B-cell activating factor (BAFF, also known as BLyS), a cytokine that supports B-cell survival and differentiation. By reducing BAFF-mediated B-cell activity, belimumab helps dampen autoimmune B-cell responses that contribute to autoantibody production and inflammatory disease activity in SLE.

Clinically, belimumab is used as an immunomodulatory treatment rather than a curative therapy. Its therapeutic role is to reduce overall lupus disease activity, lower flare risk, and help prevent cumulative organ damage in appropriately selected patients. Recent research has continued to evaluate its use across different SLE manifestations, including hematologic involvement, lupus nephritis, and pulmonary arterial hypertension associated with SLE.

Focus of Latest Publications

Recent publications on belimumab have focused on its performance across systemic lupus erythematosus disease activity outcomes and several organ-specific manifestations in both trial and real-world settings. In a post hoc analysis of five phase III SLE trials, belimumab was evaluated against placebo for attainment of modified DORIS remission and LLDAS definitions that excluded the glucocorticoid component because the trials did not mandate glucocorticoid tapering. Another analysis of phase III belimumab trial data examined how restricting disease activity assessment to a consensus “core set” of domains would affect responder classification in SLE randomized controlled trials, reflecting ongoing efforts to refine outcome measurement in lupus studies.

Several recent reports have examined belimumab in hematologic manifestations of SLE. One study reported that belimumab induces early and sustained resolution of lupus thrombocytopenia, while also considering its effects on leukopenia. A retrospective analysis from the BeRLiSS 2.0 cohort assessed belimumab effectiveness in patients with anemia, thrombocytopenia, lymphopenia, and leukopenia, further extending interest in its utility for blood-related disease features. These studies collectively indicate growing attention to belimumab’s role beyond global disease activity, particularly in hematologic involvement.

Belimumab has also been studied in lupus nephritis and in SLE-associated pulmonary arterial hypertension. A real-world retrospective observational study evaluated adjunctive belimumab therapy versus standard therapy alone in lupus nephritis, stratified by treatment phase and age, with attention to both efficacy and safety. Separately, a single-centre experience explored clinical outcomes associated with belimumab use in patients with SLE-associated pulmonary arterial hypertension. Together, these publications suggest continued investigation of belimumab as an add-on therapy across diverse and clinically challenging SLE manifestations.

Key Publications

NEWJul Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials. (RMD open, 2026, PMID 42399079): "To evaluate Definition Of Remission In SLE (DORIS) and Lupus Low Disease Activity State (LLDAS) attainment with belimumab versus placebo in a dataset of pooled phase III clinical trials in systemic lupus erythematosus (SLE) using modified definitions that excluded the glucocorticoid (GC) component ('non-GC-DORIS' and 'non-GC-LLDAS') as the trials lacked mandated GC tapering protocols."
NEWJun Belimumab as a possible treatment for SLE-associated pulmonary arterial hypertension: the experience from a single centre. (Lupus science & medicine, 2026, PMID 42315241): "To explore clinical outcomes associated with belimumab use in patients with SLE-associated pulmonary arterial hypertension (SLE-PAH)."
NEWJun Belimumab induces early and sustained resolution of lupus thrombocytopenia. (Lupus science & medicine, 2026, PMID 42309555): "Belimumab has well-established efficacy in improving overall SLE disease activity and preventing flares and organ damage."
May Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data. (Lupus science & medicine, 2026, PMID 42167880): "An analysis of phase III belimumab trial data."
May Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort. (Lupus science & medicine, 2026, PMID 42082379): "To assess the effectiveness of belimumab (BEL) in improving anaemia, thrombocytopenia, lymphopenia and leucopenia in patients with SLE."
May Efficacy and safety of belimumab in lupus nephritis: a real-world retrospective observational study stratified by treatment phase and age. (Clinical rheumatology, 2026, PMID 41811653): "This study aims to evaluate the efficacy and safety of adjunctive Belimumab therapy compared to standard therapy alone in patients with lupus nephritis (LN) within a real-world clinical setting."